Corporate News

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

Company remains EBITDA positive with further improvements in gross margin. Sales and marketing teams restructured to deliver long term growth.

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces its unaudited interim results for the six months ended 30 September 2025.

Download To view a full version of the results in  PDF format  click here

 

Operational Highlights:

• Strong performance in operations with FoodPrint® yields continuing their improvement
• CNS Lab productivity remains high with good year on year growth, sales rising 8% on last year
• Gross margin improvement driven by improved productivity and production yields, reinforcing our focus to improve this area further   

 Outlook:

• Company now expects full year sales to be lower than the previous year, as sales cycles for new customers prove to be longer than anticipated
• The sales pipeline continues to grow and the team are focused on converting initial agreements into  orders. Our revenues in H1 have not been helped by some regions, mainland Europe in particular, ordering less than in previous years.
• USA Laboratories are taking longer to commercialise FoodPrint® but we are seeing encouraging signs.  
• The Company remains well-funded to deliver on our strategic objectives, with cash being invested to drive new initiatives including IVDR development and new Gut Detective® product.
• The Board remains confident and focused on driving new and existing sales as the primary objective for H2 and the year thereafter and is increasingly spending more of its time on this area.
• Out of this has come a complete restructure of the sales team and its operations, splitting out the roles of customer service, acquisition and customer success from the sales function so they can focus primarily on signing new distributors and laboratories and driving more sales from existing customers. This feeding of the funnel is paramount to future sales growth.

¹ Adjusted for exceptional items, amortisation of intangible assets and share based payment charges.

 ² See Segment Information note 2.

 

Commenting on the results, Carolyn Rand, Chair, said:

"The first half of this year has been frustrating. We have seen some regions showing good growth, particularly where we are closer to the end user, whilst other key areas have not achieved their budget.

We have therefore implemented a restructure of the sales teams to ensure more focus is given to understand the markets more deeply and deliver on customer needs and demands. This will take a little time to embed so we do not expect the second half to show any significant improvements.

The positive news is that despite lower sales we have continued to grow our gross margin by another 2.3% in the first half and that profitability in the business continues at the adjusted EBITDA level, demonstrating the excellent work laying the foundations in these areas over the last few years.

We remain confident in the long term future of CNSL as the new sales team structure beds in and starts to deliver"

 

Investor presentation

James Cooper CEO and Ajay Patel CFO will provide a live presentation relating to the Interim Results via the Investor Meet Company platform today at 16:00 GMT. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet Cambridge Nutritional Sciences PLC  via:

https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor

The investor presentation will be available later this morning on the Company website:

https://www.cnsplc.com/financials/presentations

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

 

Contacts: 

Cambridge Nutritional Sciences PLC                                                                               www.cnsplc.com

James Cooper, Chief Executive Officer Ajay Patel, Chief Financial Officer

Cavendish Capital Markets Limited                                                                           Tel: 020 7220 0500

Nigel Birks / Harriet Ward (ECM)

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.